Patents by Inventor Gregory Oxenkrug

Gregory Oxenkrug has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS
    Publication number: 20210220298
    Abstract: The invention provides methods and compositions for use in the prevention and treatment of antipsychotic medication-induced metabolic syndrome (MetS) and diseases and conditions related to MetS.
    Type: Application
    Filed: June 28, 2019
    Publication date: July 22, 2021
    Inventors: Gregory OXENKRUG, Paul SUMMERGRAD
  • COMPOSITIONS AND METHODS FOR PROLONGING LIFESPAN
    Publication number: 20130101580
    Abstract: The present invention relates to therapeutic targets for aging. In particular, the present invention relates to the inhibition of the kynurenine pathway of tryptophan metabolism to extend lifespan or provide anti-aging benefits.
    Type: Application
    Filed: October 24, 2012
    Publication date: April 25, 2013
    Inventors: Gregory Oxenkrug, Paul Summergrad
  • Method For Inhibiting Tnf-Alpha
    Publication number: 20080234385
    Abstract: The present invention encompasses methods for inhibiting TNF-alpha expression with N-substituted dopamine derivatives. In this method a cell is administered a pharmaceutically effective amount of N-acetyl dopamine derivatives or N-alkyldopamine derivatives and a pharmaceutically acceptable carrier for treating a cell, preferably in an animal or human suffering from overexpression or abundant TNF-alpha. The N-acetyldopamine derivative or N-alkyldopamine derivatives may be administered alone or in combination with N-acetylserotonin (NAS) or other compound to inhibit TNF-alpha expression. Also disclosed is a method of treating a TNF-alpha related disease and/or disorder using such a compound.
    Type: Application
    Filed: July 26, 2006
    Publication date: September 25, 2008
    Applicant: CARITAS ST. ELIZABETH'S MEDICAL CENTER
    Inventors: Gregory Oxenkrug, Bertrand L. Jaber, Mary C. Perianayagam
  • Method for treating depression
    Publication number: 20030176488
    Abstract: The present invention relates to a method and composition for the treatment of depression in a human being identified as having depression. This method comprises the administration of a therapeutically effective depression treatment amount of M-3 agonists, 5-MCA-NAT or an analog, to a human being identified as having depression. The 5-MCA-NAT and its analogs may be administered alone or in combination with other agents, e.g. Ca++ antagonists.
    Type: Application
    Filed: March 18, 2003
    Publication date: September 18, 2003
    Inventor: Gregory Oxenkrug
  • Method for treating depression
    Patent number: 6562858
    Abstract: The present invention discloses a method for the treatment of depression in a human being identified as having depression. This method comprises the administration of a therapeutically effective depression treatment amount of M-3 agonists, 5-MCA-NAT or an analog, to said human being. The 5-MCA-NAT, or an analog, thereof may be administered alone or in combination with other agents, as Ca++ antagonists.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: May 13, 2003
    Assignee: St. Elizabeth's Medical Center of Boston, Inc.
    Inventor: Gregory Oxenkrug
  • Method for treating depression
    Publication number: 20010047016
    Abstract: The present invention relates to a method and composition for the treatment of depression in a human being identified as having depression. This method comprises the administration of a therapeutically effective depression treatment amount of M-3 agonists, 5-MCA-NAT or an analog, to a human being identified as having depression. The 5-MCA-NAT and its analogs may be administered alone or in combination with other agents, e.g. Ca++ antagonists.
    Type: Application
    Filed: April 12, 2001
    Publication date: November 29, 2001
    Inventor: Gregory Oxenkrug
  • Method for treating depression
    Patent number: 6239162
    Abstract: The present invention relates to a method of treatment of depression in a human being identified as having depression. This method comprises the administration of a therapeutically effective depression treatment amount of 5 -methoxy-carbonyl-amino-N-acetyltryptamine (5-MCA-NAT), to a human being identified as having depression. The 5-MCA-NAT may be administered alone or in combination with other agents, e.g., Cat++ antagonists.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: May 29, 2001
    Assignee: St. Elizabeth's Medical Center
    Inventor: Gregory Oxenkrug